Dalbavancin Study Results to be Presented at IDWeek 2013

CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from the company's lead product candidate, dalbavancin, will be presented in five posters during the IDWeek conference in San Francisco from October 2-6, 2013.

The following posters will be presented on Saturday, October 5, 2013:

**Title: An Analysis of the Safety Profile of Dalbavancin from the Phase 2/3 Clinical Program**

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Anita Das, PhD, InClin, San Francisco, CA and Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT

Poster #: 1334

**Title: Microbiologic Analyses of Target Pathogens Identified in the Dalbavancin DISCOVER Program**

Authors: Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL

Poster #: 1338

**Title: An Integrated Analysis of the Efficacy of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (abSSSI) from the DISCOVER Program**

Authors: Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL, Anita Das, PhD, InClin, San Francisco, CA, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT
Title: Concordance of Clinical Response at 48-72 hours after Initiation of Therapy and End of Treatment (EOT) in Patients with Acute Bacterial Skin and Skin Structure Infection (abSSSI) in the DISCOVER Studies

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL and Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA

Title: Clearance of Staphylococcus aureus Bacteremia in Patients Treated with Dalbavancin

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT and Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

About Durata Therapeutics, Inc.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute
illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.

About IDWeek 2013

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek will be held in the Moscone Convention Center, 747 Howard Street, San Francisco, CA 94103, October 2-6, 2013.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include statements about the impact of once-weekly dosing of dalbavancin. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the "Risk Factors" section of our most recent quarterly report on Form 10-Q, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

CONTACT: Investor Relations and Public Affairs Contact
Allison Wey
Durata Therapeutics
Vice President, Investor Relations and Public Affairs
(312) 219-7017
awey@duratatherapeutics.com

Media Relations Contact